Skip to main content

Physician Resources

Recently Added |view more

Transforming Urologic Care in Philadelphia and Worldwide. The Fox Chase – Temple Urologic Institute. News

Transforming Urologic Care in Philadelphia and Worldwide. The Fox Chase – Temple Urologic Institute.

In just four years, the Fox Chase – Temple Urologic Institute has leveraged the expertise of two renowned institutions to deliver an exceptionally broad range of aligned and specialized urology and urologic oncology services, led by eminent ...

Fox Chase – Temple Urologic Institute at AUA 2026 News

Fox Chase – Temple Urologic Institute at AUA 2026

Visit the Fox Chase-Temple Urologic Institute Booth #2464 in the Science & Technology Hall. 

24th Annual Highlights of the 2025 San Antonio Breast Cancer Symposium Symposium

24th Annual Highlights of the 2025 San Antonio Breast Cancer Symposium

Presented by Fox Chase Cancer Center and the Temple Health Office for Continuing Medical Education, this education program is designed to help medical, radiation, and surgical oncologists, gynecologists, and radiologists translate the ...

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy (GAIN-BCG) News

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy (GAIN-BCG)

This phase III trial compares the effect of adding gemcitabine to intravesical Bacillus Calmette Guerin (BCG) versus intravesical BCG alone in patients with non-muscle invasive bladder cancer that has come back after a period of improvement (recurrent).

Adaptive Radiation Therapy for Men with Intermediate- or High-Risk Prostate Cancer (DE-CART) News

Adaptive Radiation Therapy for Men with Intermediate- or High-Risk Prostate Cancer (DE-CART)

The goal of this clinical trial is to evaluate if adaptive stereotactic body radiation therapy (SBRT) is a safe and effective way to treat prostate cancer in adults. It will assess the safety profile of adaptive SBRT over time.

Fox Chase Cancer Center Celebrates Innovation, Sustained Growth, and Upward Momentum News

Fox Chase Cancer Center Celebrates Innovation, Sustained Growth, and Upward Momentum

When it comes to cancer, our work can seem insurmountable. But look closer, and it offers enduring hope. Despite the demands — or perhaps because of them — the faculty and staff at Fox Chase Cancer Center steadily rise above to achieve more.

The First NCI-Designated Comprehensive Cancer Center Using 3D Genomics Testing to Diagnose Lymphoma and Sarcoma—a True Game Changer News

The First NCI-Designated Comprehensive Cancer Center Using 3D Genomics Testing to Diagnose Lymphoma and Sarcoma—a True Game Changer

Diagnosing lymphoma and sarcoma can be extraordinarily complex, with more than 70 recognized subtypes of lymphoma and more than 100 distinct types of sarcoma. Many subtypes share similar features yet behave in dramatically different ways ...

Delivering Big Ideas from ASH 2025 News

Delivering Big Ideas from ASH 2025

At Fox Chase Cancer Center and Temple University Hospital, it’s “in the blood” of our residents and Fellows to develop innovative scientific ideas that significantly affect the way blood diseases are diagnosed and treated. Here is the latest from ASH 2025:

Fellowship Training That Goes Where You Go News

Fellowship Training That Goes Where You Go

As Chief Fellow Giuliana Berardi, MD, a third-year Hematology/Oncology Fellow at Fox Chase Cancer Center, reflected on her medical training, she noted the steep learning curve that accompanied each new level of medical training.